

## Human Tumor Necrosis Factor Ligand Superfamily Member 13 / CD256 (TNFSF13) Protein

Catalogue No.:abx069548



and the barrie and a second and a second second and the second

Gene sequencing extract of Tumor Necrosis Factor Ligand Superfamily Member 13 / CD256 (TNFSF13) Protein.

Recombinant Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) is a recombinant Human protein produced in a Prokaryotic expression system (E. coli).

| Target:              | Tumor Necrosis Factor Ligand Superfamily Member 13 / CD256 (TNFSF13)   |
|----------------------|--|
| Origin:              | Human  |
| Expression:          | Recombinant  |
| Tested Applications: | WB, SDS-PAGE   |
| Host:                | E. coli  |
| Conjugation:         | Unconjugated   |
| Form:                | Lyophilized  |
| Purity:              | > 97%  |
| Reconstitution:      | Reconstitute in $ddH_2O$ to a concentration of 0.1-1.0 mg/ml. Do not vortex.   |
| Storage:             | Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.  |
| v1.0.0               | Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951<br>Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413<br>Abbexa RV L eiden, NI |



## UniProt Primary AC: 075888 (UniProt, ExPASy)

| Gene Symbol:                            | TNFSF21   |
|---|---|
| GenelD:                                 | <u>8741</u>   |
| OMIM:                                   | <u>604472</u>   |
| HGNC:                                   | 11928   |
| KEGG:                                   | hsa:8741  |
| Ensembl:                                | ENSG00000161955   |
| String:                                 | 9606.ENSP00000343505  |
| Molecular Weight:<br>Sequence Fragment: | Calculated MW: 17.6 kDa<br>Observed MW (SDS-PAGE): 15 kDa<br>Possible reasons why the actual band size differs from the predicted band size:<br>1. Splice variants. Alternative splicing may create different sized proteins from the same gene.<br>2. Relative charge. The composition of amino acids may affect the charge of the protein.<br>3. Post-translational modification. Phosphorylation, glycoslyation, methylation etc. may affect the band<br>size.<br>4. Post-translational cleavage. Many proteins are synthesised as pro-proteins, and then cleaved to give<br>the active form.<br>5. Polymerisation of the target protein. Dimerisation, multimerisation etc. will increase the band size<br>observed.<br>Ala105-Leu250 |
| Sequence:                               | AVLTOK QKKQHSVLHL VPINATSKDD SDVTEVMWQP ALRRGRGLQA QGYGVRIQDA<br>GVYLLYSQVL FQDVTFTMGQ VVSREGQGRQ ETLFRCIRSM PSHPDRAYNS CYSAGVFHLH<br>QGDILSVIIP RARAKLNLSP HGTFLGFVKL  |
| Tag:                                    | N-terminal His tag  |
| Buffer:                                 | Prior to lyophilization: 100 mM NaHCO $_3$ , 500 mM NaCl, pH 8.3, containing 0.01% Sarcosyl, 5% Trehalose.  |
| Activity:                               | Not tested  |
| Concentration:                          | Prior to lyophilization: 200 μg/ml  |
| Note:                                   | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.  |